Consequences of poor compliance with bisphosphonates

Bone

Volumn 41, Issue 5, 2007, Pages 882-887

  Briesacher, Becky A ^a   Andrade, Susan E ^a   Yood, Robert A ^a   Kahler, Kristijan H ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bisphosphonates; Health care costs; Patient compliance

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HEALTH CARE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; RISK FACTOR;

COHORT STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES;

EID: 35348866074     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.07.009     Document Type: Article

References (26)

1. Adami S., Isaia G., Luisetto G., Minisola S., Sinigaglia L., Gentilella R., et al. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21 (2006) 1565-1570
2. Ash A.S., Ellis R.P., Pope G.C., Ayanian J.Z., Bates D.W., Burstin H., et al. Using diagnoses to describe populations and predict costs. Health Care Financ Rev 21 (2000) 7-28
3. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348 (1996) 1535-1541
4. Black D.M., Thompson D.E., Bauer D.C., Ensrud K., Musliner T., Hochberg M.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85 (2000) 4118-4124
5. Briesacher B.A., Orwig D., Seton M., Omar M., and Kahler K.H. Medical care costs of Paget's disease of bone in a privately insured population. Bone 38 (2006) 731-737
6. Caro J.J., Ishak K.J., Huybrechts K.F., Raggio G., and Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15 (2004) 1003-1008
7. Cramer J.A., Amonkar M.M., Hebborn A., and Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21 (2005) 1453-1460
8. Cramer J.A., and Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 119 (2006) S12-S17
9. Duan N., Manning W.G., Morris C.N., and Newhouse J.P.A. A comparison of alternative models for the demand of medical care. J Bus Econ Stat 1 (1983) 115-126
10. Emkey R., Delmas P.D., Goemaere S., Liberman U.A., Poubelle P.E., Daifotis A.G., et al. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study. Arthritis Rheum 48 (2003) 1102-1108
11. Ensrud K.E., Barrett-Connor E.L., Schwartz A., Santora A.C., Bauer D.C., Suryawanshi S., et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19 (2004) 1259-1269
12. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282 (1999) 1344-1352
13. Huybrechts K.F., Ishak K.J., and Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38 (2006) 922-928
14. McCombs J.S., Thiebaud P., McLaughlin-Miley C., and Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48 (2004) 271-287
15. Ohsfeldt R.L., Borisov N.N., and Sheer R.L. Fragility fracture-related direct medical costs in the first year following a nonvertebral fracture in a managed care setting. Osteoporos Int 177 (2006) 252-258
16. Patel S., Kwan J.T., McCloskey E., McGee G., Thomas G., Johnson D., et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res 16 (2001) 1863-1870
17. Ray W.A., Daugherty J.R., and Griffin M.R. Lipid-lowering agents and the risk of hip fracture in a Medicaid population. Inj Prev 8 (2002) 276-279
18. Recker R.R., Gallagher R., and MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80 (2005) 856-861
19. Siris E.S., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81 (2006) 1013-1022
20. Solomon D.H., Avorn J., Katz J.N., Finkelstein J.S., Arnold M., Polinski J.M., et al. Compliance with osteoporosis medications. Arch Intern Med 165 (2005) 2414-2419
21. Tosteson A.N., Grove M.R., Hammond C.S., Moncur M.M., Ray G.T., Hebert G.M., et al. Early discontinuation of treatment for osteoporosis. Am J Med 115 (2003) 209-216
22. White H.D. Adherence and outcomes: it's more than taking the pills. Lancet 366 (2005) 1989-1991
23. Yood R.A., Emani S., Reed J.I., Lewis B., Charpentier E., and Lydick M. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14 (2003) 965-968
24. Zeger S.L., and Liang K.Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 42 (1986) 121-130
25. Zeger S.L., Liang K.Y., and Albert P.S. Models for longitudinal data: a generalized estimating equation approach. Biometrics 44 (1988) 1049-1060
26. Zhao Y., Ellis R.P., Ash A.S., Calabrese D., Ayanian J.Z., Slaughter J.P., et al. Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Serv Res 36 (2001) 180-193